drugset

drugset / Trial / NCT02597153

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

NCT02597153 ↗

Phase 2 Terminated 1 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell

Timeline

Start: 2015-10
Primary completion: 2017-10
Completion: 2020-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mitoxantrone	Small molecule	20 mg/m2	—

Indications